Publication date: Available online 6 November 2026 Source: Disease and Therapeutics Author(s): Jarrett J. Adams, Yun Hye Kim, Kris Barreto, Wendy Bernhard, Kate Muzalevska, Andres Medina Salguero, Craig A. Hokanson, Valeria Castano, Ryan Liang, Nick Jarvik, Chao Chen, Maryna Gorelik, Lynda Ploder, Julia Garcia, Isabelle Pot, C. Ronald Geyer, Stephane Angers, Sachdev S. Sidhu
Tumor-homing Bispecific Antibodies that Co-engage EPHA2 and Frizzled Receptors Target RNF43-mutant Pancreatic Cancer and Minimize Toxicity. // Disease and Therapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S3050999826000253?dgcid=rss_sd_all
Tumor-homing Bispecific Antibodies that Co-engage EPHA2 and Frizzled Receptors Target RNF43-mutant Pancreatic Cancer and Minimize Toxicity. Disease and Therapeutics. https://www.sciencedirect.com/science/article/pii/S3050999826000253?dgcid=rss_sd_all
“Tumor-homing Bispecific Antibodies that Co-engage EPHA2 and Frizzled Receptors Target RNF43-mutant Pancreatic Cancer and Minimize Toxicity.” Disease and Therapeutics.
@article{article43298,
title = {Tumor-homing Bispecific Antibodies that Co-engage EPHA2 and Frizzled Receptors Target RNF43-mutant Pancreatic Cancer and Minimize Toxicity},
journal = {Disease and Therapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S3050999826000253?dgcid=rss_sd_all}
}
Publication date: November–December 2026 Source: Acta Otorrinolaringologica (English Edition), Volume 77, Issue 6 Author(s): Daniel Álvarez de Castro, Sandra Pérez de la Iglesia, Miguel Ramírez Verdyguer, Francisco José Manzano Gómez